Oral 17β-estradiol and sequential progesterone in menopause: Effects on insulin-like growth factors and their binding proteins

Gynecological Endocrinology

Volumn 23, Issue 1, 2007, Pages 50-57

  Mozzanega, Bruno ^a   Babbo, Gian Luca ^a   Salmaso, Luigi ^a   De Toni, Renzo ^a   Schiavo, Alessandra ^a   Mioni, Roberto ^a   De Kreutzenberg, Saula Vigili ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Estradiol; Growth hormone; Hormone replacement therapy; Insulin like growth factor binding proteins 1 and 3; Insulin like growth factors I and II; Progesterone; Sex hormone binding globulin

Indexed keywords

C PEPTIDE; ESTRADIOL; ESTROFEM; ESTROGEN; GROWTH HORMONE; INSULIN; PROGESTERONE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; PLASMA PROTEIN; SOMATOMEDIN C;

ADULT; ARTICLE; BLOOD CLOTTING DISORDER; BREAST; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOMETRIUM; ESTRADIOL BLOOD LEVEL; FEMALE; HORMONE SUBSTITUTION; HUMAN; KIDNEY DISEASE; LIVER CELL; LOW DRUG DOSE; MENOPAUSAL SYNDROME; MENOPAUSE; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ULTRASOUND; X RAY; BLOOD; DRUG ADMINISTRATION; DRUG EFFECT; ESTROGEN THERAPY; INTRAVAGINAL DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, ORAL; BLOOD PROTEINS; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR I; MENOPAUSE; MIDDLE AGED; PROGESTERONE; SEX HORMONE-BINDING GLOBULIN;

EID: 33847079259     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590601137095     Document Type: Article

References (55)

1. Rutanen EM. Insulin-like growth factors in endometrial function. Gynecol Endocrinol 1998;12:399-406.
2. Le Roith D. Insulin-like growth factors. N Engl J Med 1977;336:633-640.
3. Nasu M, Sugimoto T, Chihara M, Hiraumi M, Kurimoto F, Chihara K. Effect of natural menopause on serum levels of IGF-I and IGF-binding proteins: relationship with bone mineral density and lipid metabolism in perimenopausal women. Eur J Endocrinol 1997;136:608-616.
4. Cano A, Castelo-Branco C, Tarìn JJ. Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone-stimulated serum growth hormone, insulin-like growth factor-I, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 levels. Fertil Steril 1999;71:261-267.
5. Dunn SE, Hardman RA, Kary FW, Barrett JC. Insulin-like growth factor I (IGF-I) alters drug sensitivity of HBL 100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 1997;57:2687-2693.
6. Gooch JL, Van Den Berg CL, Yee D. Insulin-like growth factor I (IGF-I) rescues breast cancer cells from chemotherapy-induced cell death and anti-apoptotic effects. Breast Cancer Res Treat 1999;56:1-10.
7. Stewart AJ, Johnson MD, May FE, Westley BR. Role of insulin-like growth factor-I and the type 1 insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 1990;265:21172-21178.
8. Thorsen T, Lahooti H, Rasmussen M, Aakvaag A. Oestradiol treatment increases the sensitivity of MCF-7 cells for the growth stimulatory effect of IGF-I. J Steroid Biochem Mol Biol 1992;41:537-540.
9. Huynh H, Yang X, Pollak M. Estradiol and anti-estrogens regulate a growth inhibitory insulin-like growth factor binding protein-3 autocrine loop in human breast cancer cells. J Biol Chem 1996;271:1016-1021.
10. Byrne C, Colditz GA, Willet WC, Speizer FE, Pollak M, Hankinson SE. Plasma insulin-like growth factor (IGF)-I, IGF-binding protein-3 and mammographic density. Cancer Res 2000;60:3744-3748.
11. Hankinson SE, Willett WC, Colditz GA, Hunter DJ. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-1396.
12. Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS. Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 1998;9:570-573.
13. Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrer JM, Koenig KL, Lukanova A, Shore RE, Zeleniuch-Jacquotte A. Serum insulin-like growth factor-I and breast cancer. Int J Cancer 2000;88:828-832.
14. Agurs-Collins T, Adams-Campbell LL, Kim KS, Cullen KJ. Insulin-like growth factor-I and breast cancer risk in postmenopausal African-American Women. Cancer Detect Prev 2000;24:199-206.
15. Kaaks R, Lundin E, Rinaldi S, Manjer J, Biessy C, Soderberg S, Lenner P, Janzon L, Riboli E, Berglund G, et al. Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control 2002;13:307-316.
16. Yu H, Jin F, Shu XO, Li BD, Dai Q, Cheng JR, Berkel HJ, Zheng W. Insulin-like growth factors and cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 2002;11:705-712.
17. Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, Dechaud H, Rinaldi S, Zeleniuch-Jacquotte A, Shore RE, Riboli E. Serum C-peptide, serum insulin-like growth factor (IGF)-I, IGF-binding proteins and colorectal cancer risk in women. J Natl Cancer Inst 2000;92:1592-1600.
18. Manousos O, Souglakos J, Bosetti C, Tzonou A, Chatzidakis V, Trichopoulos D, Adami HO, Mantzoros C. IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer 1999;83:15-17.
19. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92:1472-1489.
20. Stewart CE, Rothwein P. Growth, differentiation and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev 1996;76:1005-1026.
21. Murphy LJ. Insulin-like growth factor binding proteins: functional diversity or redundancy? J Mol Endocrinol 1998;21:97-107.
22. Mohan S. Insulin-like growth factor (IGF)-binding proteins in serum - do they have additional roles besides modulating the endocrine IGF actions? J Clin Endocrinol Metab 1996;81:3817-3820.
23. Westwood M, Gibson JM, Williams AC, Clayton PE, Hamberg O, Flyvbjerg A, White A. Hormonal regulation of circulating insulin-like growth factor-binding protein-1 phosphorylation status. J Clin Endocrinol Metab 1995;80:3520-3527.
24. Bellantoni MF, Vittone J, Campfield AT. Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor-I axis in younger and older postmenopausal women: a clinical research center study. J Clin Endocrinol Metab 1996;81:2848-2853.
25. Campagnoli C, Biglia N, Sismondi P. Differential effects of oral conjugated estrogens and transdermal estradiol on insulinlike growth factor-I, growth hormone and sex hormone binding globulin serum levels. Gynecol Endocrinol 1993;7:251-258.
26. Helle SI, Omsjo IH, Botta L. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins-1 and -3: a crossover study. Clin Endocrinol (Oxf) 1996;45:727-732.
27. Dawson-Hughes B, Stern D. Regulation of growth hormone and somatomedin-C secretion in menopausal women: effect of physiological estrogen replacement. J Clin Endocrinol Metab 1986;63:424-432.
28. Campagnoli C, Biglia N, Peris C, Sismondi P. Potential impact on breast cancer risk of circulating insulin-like growth factor-I modifications induced by oral HRT in menopause. Gynecol Endocrinol 1995;9:67-74.
29. Campagnoli C, Biglia N, Cantamessa C. Effect of progestins on IGF I serum level in estrogen-treated postmenopausal women. Zentralbl Gynakol 1997;119:7-11.
30. Weissberger AJ, Ho KKY. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor-I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 1991;72:374-381.
31. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. Classification and pharmacology of progestins. Maturitas 2003;46(Suppl 1):S7-S16.
32. Heald A, Selby PL, White A, Gibson JM. Progestin abrogates estrogen-induced changes in the insulin-like growth factor axis. Am J Obstet Gynecol 2000;183:593-600.
33. Ludbrook J, Dudley H. Why permutation tests are superior to t and F tests in biomedical research. Am Statistician 1998;52:127-132.
34. Celant G, Pesarin F, Salmaso L. Some comparisons between a parametric and a nonparametric solution for tests with repeated measures. Metron 2000;58:65-79.
35. Corain L, Salmaso L. Multivariate and multistrata nonparametric tests: the nonparametric combination method. J Mod Appl Stat Meth 2004;3D:443-461.
36. Salmaso L, Solari A. Multiple aspect testing for case-control designs. Metrica 2005;62:331-340.
37. Campagnoli C, Biglia N, Lanza M. Androgenic progestins oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report. Maturitas 1994;19:25-31.
38. Fornander T, Wilking N. Oestrogenic effects of adjuvant tamoxifen in postmenopausal breast cancer. Eur J Cancer 1993;29A:497-500.
39. Huynh HT, Tetenes E. In vivo inhibition of insulin-like growth factor-I gene expression by tamoxifen. Cancer Res 1993;53:1727-1730.
40. Lonning PE, Hall K. Influence of tamoxifen on plasma levels of insulin-like growth factor-I and insulin-like growth factor binding protein-1 in breast cancer patients. Cancer Res 1992;52:4719-4723.
41. Ferrari L, Martinetti A, Zilembo N, Pozzi P, Buzzoni R, La Torre I, Gattinoni L, Catena L, Vitali M, Celio L, et al. Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients. J Steroid Biochem Mol Biol 2002;80:411-418.
42. Poiraudeau S, Roux C, De Ceuninck F, Tsagris L, Borderie D, Cherruau B, Dumontier MF, Corvol M. Circulating insulin-like growth factor system changes in women with acute estrogen deficiency induced by GnRH agonist. Osteoporos Int 1977;7:463-470.
43. Friend KE, Hartman ML, Pezzoli SS. Both oral and transdermal estrogen increase growth hormone release in postmenopausal women - a clinical research center study. J Clin Endocrinol Metab 1996;81:2250-2256.
44. Price TM, Blauer KL, Hansen M. Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17β estradiol. Obstet Gynecol 1997;89:340-345.
45. Marchesoni D, Mozzanega B, Vesnaver S, Dal Pozzo M, Donè E, Schiavo A, Andrisani A, Ambrosini A. Hormone replacement therapy in menopause: variations in insulin-like growth factor-I and sex hormone binding globulin serum levels. Int J Gynecol Obstet 2000;12:104-109.
46. Murphy LJ, Friesen HG. Differential effects of estrogen and growth hormone on uterine and hepatic insulin-like growth factor-I gene expression in the ovariectomized hypophysectomized rat. Endocrinology 1988;122:325-332.
47. Moyano P, Rotwein P. Mini review: estrogen action in the uterus and insulin-like growth factor-I. Growth Horm IGF Res 2004;14:431-435.
48. Arany E, Afford S, Strain AJ, Winwood PJ, Arthur MJP, Hill DJ. Differential cellular synthesis of insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-3 within human liver. J Clin Endocrinol Metab 1994;79:1871-1876.
49. Meinhardt UJ, Ho KKY. Modulation of growth hormone action by sex steroids. Clin Endocrinol (Oxf) 2006;65:413-422.
50. Toscano V, Balducci R, Bianchi P, Guglielmi R, Mangiantini A, Sciarra F. Steroidal and nonsteroidal factors in plasma sex hormone binding globulin regulation. J Steroid Biochem Mol Biol 1992;43:431-437.
51. Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 1987;67:460-464.
52. Peyrat JP, Bonneterre J. Insulin-like growth factor-I receptors (IGF I-R) and IGF-I in human breast tumors. J Steroid Biochem Mol Biol 1990;37:823-827.
53. Perks CM, Newcomb PW, Norman NR, Holly JMP. Effect of insulin-like growth factor binding protein-1 on integrin signalling and the induction of apoptosis in human breast cancer. J Mol Endocrinol 1999;22:141-150.
54. Nugent AG, Leung KC, Sullivan D, Reutens AT, Ho KK. Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women. Clin Endocrinol (Oxf) 2003;59:690-698.
55. Cicinelli E, de Ziegler D, Bulletti C, Matteo MG, Schonauer LM, Galantino P. Direct transport of progesterone from vagina to uterus. Obstet Gynecol 2000;95:403-406.